For the quarter ending 2025-09-30, IVF had -$193,290 decrease in cash & cash equivalents over the period. -$1,784,599 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,644,625 | -22,688,444 |
| Stock compensation issued for services | 481,430 | 668,805 |
| Fair value of stock options issued to employees | 11,918 | 82,530 |
| Non-cash compensation for services | 45,000 | 90,000 |
| Amortization of discount on notes payable | 1,736 | 130,908 |
| Loss (gain) from equity method investment | 12,827 | -4,815 |
| Loss from debt extinguishment | -876,165 | -692,270 |
| Gain on lease termination | - | 0 |
| Loss from disposal of assets | - | 0 |
| Impairment loss | 0 | 16,042,422 |
| Loss on disposition | 0 | -1,534,517 |
| Stock compensation issued to directors and employees | - | 0 |
| Gain on settlement | 840,500 | 774,500 |
| Depreciation and amortization | 136,741 | 404,198 |
| Accounts receivable | 31,945 | 67,374 |
| Inventory | -20,849 | -7,153 |
| Prepaid expenses and other current assets | -80,354 | 274,633 |
| Accounts payable and accrued expenses | 245,194 | -689,107 |
| Accrued compensation | -22,737 | 216,480 |
| Deferred revenue | -114,443 | 232,491 |
| Other current liabilities | 0 | -1,000,000 |
| Leasehold liability | 1,887 | 9,407 |
| Accrued interest | -10,734 | 114,907 |
| Net cash used in operating activities | -1,776,537 | -5,263,155 |
| Proceeds from sale of fixed assets | - | 0 |
| Payments to acquire property, plant, and equipment | 8,062 | 23,527 |
| Divesture of naya | 0 | 6,569 |
| Net cash used in investing activities | -8,062 | -30,096 |
| Proceeds from the sale of notes payable | - | 0 |
| Proceeds from the sale of common stock, net of offering costs | 0 | 8,747,902 |
| Proceeds from sale of preferred stock | 1,650,000 | 500,000 |
| Proceeds from warrant exercise | 19,566 | 1,024,637 |
| Preferred stock redemption | 0 | 4,000,000 |
| Principal payments on notes payable | 78,257 | 1,171,503 |
| Net cash provided by financing activities | 1,591,309 | 5,101,036 |
| Increase (decrease) in cash and cash equivalents | -193,290 | -192,215 |
| Cash and cash equivalents at beginning of period | 741,396 | - |
| Cash and cash equivalents at end of period | 355,891 | - |
INVO Fertility, Inc. (IVF)
INVO Fertility, Inc. (IVF)